Format

Send to

Choose Destination
Oncotarget. 2016 Aug 2;7(31):49075-49090. doi: 10.18632/oncotarget.8682.

Efficient therapeutic delivery by a novel cell-permeant peptide derived from KDM4A protein for antitumor and antifibrosis.

Wang H1,2,3, Ma JL2, Yang YG1,2, Song Y1,2,3, Wu J1,2,3, Qin YY2,3, Zhao XL2,3, Wang J1,4, Zou LL1,2, Wu JF1,2, Li JM1,4, Liu CB1,2,3.

Author information

1
The Institute of Cell Therapy, China Three Gorges University, Yichang 443002, China.
2
Medical School, China Three Gorges University, Yichang 443002, China.
3
Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang 443002, China.
4
The 1st People's Hospital of Yichang, Yichang 443000, China.

Abstract

Cell-penetrating peptide (CPP) based delivery have provided immense potential for the therapeutic applications, however, most of nonhuman originated CPPs carry the risk of possible cytotoxicity and immunogenicity, thus may restricting to be used. Here, we describe a novel human-derived CPP, denoted hPP10, and hPP10 has cell-penetrating properties evaluated by CellPPD web server, as well as In-Vitro and In-Vivo analysis. In vitro studies showed that hPP10-FITC was able to penetrate into various cells including primary cultured cells, likely through an endocytosis pathway. And functionalized macromolecules, such as green fluorescent protein (GFP), tumor-specific apoptosis inducer Apoptin as well as biological active enzyme GCLC (Glutamate-cysteine ligase, catalytic subunit) can be delivered by hPP10 in vitro and in vivo. Collectively, our results suggest that hPP10 provide a novel and versatile tool to deliver exogenous proteins or drugs for clinical applications as well as reprogrammed cell-based therapy.

KEYWORDS:

GFP; anti-tumor; cell-penetrating peptides (CPPs); internalization; melanoma

PMID:
27081693
PMCID:
PMC5226491
DOI:
10.18632/oncotarget.8682
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center